Brokerages Expect Solid Biosciences (SLDB) to Announce -$0.43 EPS

Equities analysts expect Solid Biosciences (NASDAQ:SLDB) to post earnings of ($0.43) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Solid Biosciences’ earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.45). The business is expected to report its next earnings results on Thursday, July 5th.

On average, analysts expect that Solid Biosciences will report full-year earnings of ($1.92) per share for the current fiscal year, with EPS estimates ranging from ($2.24) to ($1.67). For the next year, analysts forecast that the business will post earnings of ($1.88) per share, with EPS estimates ranging from ($2.24) to ($1.53). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Solid Biosciences.

Several brokerages have issued reports on SLDB. JPMorgan Chase lowered shares of Solid Biosciences from a “neutral” rating to an “underweight” rating and set a $28.00 price target on the stock. in a research note on Thursday, March 15th. Leerink Swann began coverage on shares of Solid Biosciences in a research note on Tuesday, February 20th. They issued an “outperform” rating and a $36.00 price target on the stock. Goldman Sachs began coverage on shares of Solid Biosciences in a research note on Tuesday, February 20th. They issued a “neutral” rating and a $31.00 price target on the stock. Nomura began coverage on shares of Solid Biosciences in a research note on Tuesday, February 20th. They issued a “buy” rating and a $52.00 price target on the stock. Finally, Instinet began coverage on shares of Solid Biosciences in a research note on Tuesday, February 20th. They issued a “buy” rating and a $52.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. Solid Biosciences currently has an average rating of “Hold” and a consensus target price of $33.67.



In other Solid Biosciences news, Director Life Sciences Maste Perceptive purchased 1,020,000 shares of the stock in a transaction on Tuesday, January 30th. The shares were purchased at an average cost of $16.22 per share, for a total transaction of $16,544,400.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

SLDB stock traded up $0.04 during midday trading on Thursday, hitting $10.09. The company’s stock had a trading volume of 82,815 shares, compared to its average volume of 393,069. Solid Biosciences has a twelve month low of $6.83 and a twelve month high of $33.74. The firm has a market capitalization of $353.70 and a P/E ratio of -3.50.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://dakotafinancialnews.com/2018/04/12/brokerages-expect-solid-biosciences-sldb-to-announce-0-43-eps.html.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing various therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, an adeno-associated viral vector-mediated gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles.

Get a free copy of the Zacks research report on Solid Biosciences (SLDB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply